| Literature DB >> 35072278 |
Rohit Dhakal1,2, Rakhee Shah2, Byki Huntjens2, Pavan K Verkicharla1, John G Lawrenson2.
Abstract
PURPOSE: Outdoor light exposure is considered a safe and effective strategy to reduce myopia development and aligns with existing public health initiatives to promote healthier lifestyles in children. However, it is unclear whether this strategy reduces myopia progression in eyes that are already myopic. This study aims to conduct an overview of systematic reviews (SRs) reporting time spent outdoors as a strategy to prevent myopia or slow its progression in children.Entities:
Keywords: Myopia; children; intervention; light exposure; outdoor time; overview
Mesh:
Year: 2022 PMID: 35072278 PMCID: PMC9305934 DOI: 10.1111/opo.12945
Source DB: PubMed Journal: Ophthalmic Physiol Opt ISSN: 0275-5408 Impact factor: 3.992
Characteristics of included systematic reviews in the overviews
| Review (Study design) | Number and name of databases searched (last date of search) | No. of primary studies included & type of study design | Definition of myopia | Total population included in review | Ethnicity & age groups (years) | Details of intervention | Review outcomes |
|---|---|---|---|---|---|---|---|
| Sherwin et al. | 4, MEDLINE, Web of Science, EMBASE and CENTRAL (Sept 2011) | 23; 15 CS, 7 cohort and 1 RCT. MA was performed only in 7 CS | ≤−0.50 D | 23,739 | Caucasian, Turkish, Asian; 0.5–20 |
|
|
| Xiong et al. | 3, PubMed, EMBASE and Cochrane library (Dec 2015) | 51; 4 CT, 17 cohort studies, and 30 CS. MA was performed in 25 studies | NR | 72,327 | Chinese, Caucasian, Indian, Malays, Mongolian, East Asian, African‐American, Turkish; 4–79 |
|
|
| Deng and Pang | 6, Scopus, MEDLINE, EMBASE, VisionCite, PubMed and Cochrane library (March 2016) | 5; 2 RCT, 2 cluster RCT and 1 NR about randomization | NR | 3,272 | Chinese; 6–18 |
|
|
| Ho et al. | 6, Cochrane Library, MEDLINE, CINAHL, PubMed, China Academic Journals full‐text database and National Digital Library of Theses and Dissertations in Taiwan (2019) | 13; 6 CT, 3 cohort studies, and 4 CS | NR | 15,081 | Chinese, East Asian, Hispanic, Caucasian; 4–14 |
|
|
| Cao et al. | 5, PubMed, Science Direct, Cochrane Library, Chinese National Knowledge Infrastructure and Wanfang (Oct 2018) | 5; 1 RCT, 4 cluster RCT | <−0.50 D | 3,014 | Chinese; 6–12 |
|
|
| Anandita and Barliana | 1, MEDLINE (NR) | 13; 8 CS, 5 Cohort | Ranged from <−0.50 to ≤−1.00 D | 29,301 | Chinese, East Asian, African, Caucasian, Arabian, Hispanic; 0–18 |
|
|
| Eppenberger and Sturm | 2, PubMed and Cochrane Library (Jan 2019) | 12; 3 CT, 7 cohort and 2 CS | Ranged from ≤−0.50 to ≤−1.00 D | 32,381 | Chinese, Malay, East Asian, Indian, African, Hispanic; 6–18 |
|
|
Abbreviations: CS, Cross‐sectional; CT, Clinical trial; MA, Meta‐analysis; NR, Not reported; RCT, Randomised clinical trial; ROC, Recess outside classroom; SER, Spherical equivalent refraction; SR, Systematic review; TSO, Time spent outdoors.
FIGURE 1Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow diagram presenting the process of study identification, screening and selection of systematic reviews
Methodological quality of the included systematic reviews as judged by the AMSTAR‐2 instrument
| Items | Deng and Pang | Sherwin et al. | Anandita and Barliana | Xiong et al. | Ho et al. | Cao et al. | Eppenberger and Sturm |
|---|---|---|---|---|---|---|---|
| 1. Did the research questions and inclusion criteria for the review include the components of PICO? | |||||||
| 2. Did the report of the review contain an explicit statement that the review methods were established prior to conduct of the review and did the report justify any significant deviations from the protocol? | |||||||
| 3. Did the review authors explain their selection of the study designs for inclusion in the review? | |||||||
| 4. Did the review authors use a comprehensive literature search strategy? | |||||||
| 5. Did the review authors perform study selection in duplicate? | |||||||
| 6. Did the review authors perform data extraction in duplicate? | |||||||
| 7. Did the review authors provide a list of excluded studies and justify the exclusions? | |||||||
| 8. Did the review authors describe the included studies in adequate detail? | |||||||
| 9. Did the review authors use a satisfactory technique for assessing the risk of bias (ROB) in individual studies that were included in the review? | |||||||
| 10. Did the review authors report on the sources of funding for the studies included in the review? | |||||||
| 11. If meta‐analysis was justified, did the review authors use appropriate methods for statistical combination of results? | |||||||
| 12. If meta‐analysis was performed, did the review authors assess the potential impact of ROB in individual studies on the results of the meta‐analysis or other evidence synthesis? | |||||||
| 13. Did the review authors account for ROB in individual studies when interpreting/ discussing the results of the review? | |||||||
| 14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? | |||||||
| 15. If they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? | |||||||
| 16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review? |
Abbeviations: PICO, Patient Intervention Comparator Outcom.
Note: Colour coding indicates whether the study satisfied each AMSTAR‐2 item. Red = no; Green = yes; Blue = partially yes, and Yellow = not applicable. The grey shaded items represent critically important domains.
FIGURE 2Graphical representation of Risk of Bias Assessment Tool for Systematic Reviews (ROBIS) assessment in seven included systematic reviews
Myopia prevalence reported in included systematic reviews and meta‐analyses
| Review study | Number of subjects (Number and design of primary studies) | Duration of effect (years) | Measure of effect (95% CI) | Direction of effect |
|---|---|---|---|---|
| Sherwin et al. | 9,885 (7, CS) | NA | OR 0.98 (0.97, 0.99) | Favours high outdoor exposure |
| Xiong et al. | 23,112 (13, CS) | NA | OR 0.96 (0.94, 0.98) | Favours high outdoor exposure |
| Ho et al. | 5,745 (4, CS) | NA | OR 0.95 (0.92, 0.99) | Favours high outdoor exposure |
Abbreviations: CI, Confidence interval; CS, Cross‐sectional studies; NA, Not applicable; OR, Odds ratio.
FIGURE 3Forest plot showing pooled estimates of association between outdoor light exposure and myopia prevalence
Myopia incidence reported in included systematic reviews and meta‐analyses
| Review study | Number of subjects (Number and design of primary studies) | Duration of effect (years) | Measure of effect (95% CI) | Measure of effect standardised to RR (95% CI) | Direction of effect |
|---|---|---|---|---|---|
| Xiong et al. | 2,865 (3, CT) | 3 | RR 0.54 (0.34, 0.85) | RR 0.54 (0.34, 0.85) | Favours high outdoor exposure |
| Deng and Pang | 2,885 (4, CT) | 1 | RR 0.66 (0.49, 0.89) | RR 0.66 (0.49, 0.89) | Favours high outdoor exposure |
| Cao et al. | 2,590 (3, CT) | NR | RR 0.76 (0.67, 0.87) | RR 0.76 (0.67, 0.87) | Favours high outdoor exposure |
| Ho et al. | 4,714 (5, CT) | 1 | OR 0.50 (0.37, 0.69) | RR 0.54 (0.37, 0.79) | Favours high outdoor exposure |
| Xiong et al. | 4,064 (2, Cohort) | 3 | RR 0.57 (0.40, 0.83) | RR 0.57 (0.40, 0.83) | Favours high outdoor exposure |
| Ho et al. | 4,622 (3, Cohort) | 1 | OR 0.57 (0.35, 0.92) | RR 0.61 (0.41, 0.92) | Favours high outdoor exposure |
Abbreviations: CI, Confidence interval; CT, Clinical trial; NR, Not reported; OR, Odds ratio; RR, Risk ratio.
FIGURE 4Forest plot showing pooled estimates of myopia incidence over a period of 1 year from baseline. *Reported change in 3 years
Change in spherical equivalent refractive error reported in included systematic reviews and meta‐analyses
| Review study | Number of subjects (Number and design of primary studies) | Duration of effect (years) | Measure of effect (D), MD (95% CI) | Measure of effect standardised to 1 year (D) MD (95% CI) | Direction of effect |
|---|---|---|---|---|---|
| Xiong et al. | 2,865 (3, CT) | 3 | 0.30 (0.18, 0.41) | 0.13 (0.08, 0.18) | Favours high outdoor exposure |
| Ho et al. | 4,406 (6, CT) | 1 | 0.15 (0.09, 0.22) | 0.15 (0.09, 0.22) | Favours high outdoor exposure |
| Cao et al. | 2,729 (4, CT) | NI | 0.17 (0.16, 0.18) | 0.17 (0.16, 0.18) | Favours high outdoor exposure |
| Deng and Pang | 3,272 (5, CT) | 1 | 0.13 (0.08, 0.18) | 0.13 (0.08, 0.18) | Favours high outdoor exposure |
Abbreviations: CI, Confidence interval; CT, Clinical trials; D, Dioptres; MD, Mean difference.
FIGURE 5Forest plot showing pooled estimates of change in spherical equivalent refraction (SER) from baseline (1 year). *Did not report duration over which change was assessed
Change in axial length reported in included systematic reviews and meta‐analyses
| Review study | Number of subjects (Number and design of primary studies) | Duration of effect (years) | Measure of effect (mm) (95% CI) | Direction of effect |
|---|---|---|---|---|
| Deng and Pang | 2,658 (3, CT) | 1 | MD −0.03 (−0.05, 0.00) | Favours high outdoor exposure |
| Cao et al. | 2,658 (3, CT) | NI | MD −0.03 (−0.03, −0.03) | Favours high outdoor exposure |
| Ho et al. | 3,903 (4, CT) | 1 | MD −0.08 (−0.14, −0.02) | Favours high outdoor exposure |
Abbreviations: CI, Confidence interval; CT, Clinical trials; MD, Mean difference.
FIGURE 6Forest plot showing pooled estimates of change in axial length from baseline (1 year). *Did not report duration over which change was assessed